Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ga-68 PSMA-HBED-CC PET in Metastatic Prostate Cancer
NCT02952469Phase 1Completed
- Sponsor
- University of Iowa
- Start
- Jul 2016
- Primary completion
- Apr 2022
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of gallium ga-68 gozetotide in prostate cancer (PCa), sponsored by University of Iowa. Primary endpoint: Reproducibility assessment at 15 days. Started Jul 2016; status: completed.
02
Drugs
gallium ga-68 gozetotide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02952469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02952469.